SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,576,568 | +247.0% | 383,626 | +278.4% | 0.00% | +100.0% |
| Q2 2023 | $3,047,693 | -24.7% | 101,387 | -9.3% | 0.00% | 0.0% |
| Q1 2023 | $4,048,847 | -71.7% | 111,754 | -72.2% | 0.00% | -66.7% |
| Q4 2022 | $14,326,321 | +36.7% | 401,635 | +29.7% | 0.00% | +50.0% |
| Q3 2022 | $10,483,000 | +245.2% | 309,691 | +194.9% | 0.00% | +100.0% |
| Q2 2022 | $3,037,000 | -28.4% | 105,020 | -20.0% | 0.00% | 0.0% |
| Q1 2022 | $4,242,000 | -7.5% | 131,261 | -16.6% | 0.00% | 0.0% |
| Q4 2021 | $4,588,000 | +262.1% | 157,315 | +230.9% | 0.00% | – |
| Q3 2021 | $1,267,000 | -91.1% | 47,535 | -89.7% | 0.00% | -100.0% |
| Q2 2021 | $14,217,000 | +427.5% | 461,723 | +348.5% | 0.00% | – |
| Q1 2021 | $2,695,000 | +104.6% | 102,956 | +96.6% | 0.00% | – |
| Q4 2020 | $1,317,000 | +107.1% | 52,376 | +71.7% | 0.00% | – |
| Q3 2020 | $636,000 | -11.0% | 30,500 | +1.3% | 0.00% | – |
| Q2 2020 | $715,000 | -94.6% | 30,100 | -95.9% | 0.00% | -100.0% |
| Q1 2020 | $13,239,000 | +88.9% | 735,840 | +149.1% | 0.01% | +100.0% |
| Q4 2019 | $7,008,000 | -4.4% | 295,456 | +10.7% | 0.00% | 0.0% |
| Q3 2019 | $7,334,000 | +32.5% | 266,920 | +59.5% | 0.00% | +50.0% |
| Q2 2019 | $5,537,000 | -21.2% | 167,355 | -16.6% | 0.00% | -50.0% |
| Q1 2019 | $7,031,000 | +98.2% | 200,638 | +87.9% | 0.00% | +300.0% |
| Q4 2018 | $3,548,000 | -35.7% | 106,792 | -2.5% | 0.00% | -66.7% |
| Q3 2018 | $5,517,000 | -22.4% | 109,564 | -7.8% | 0.00% | 0.0% |
| Q2 2018 | $7,108,000 | -37.3% | 118,774 | -52.0% | 0.00% | -50.0% |
| Q1 2018 | $11,333,000 | +438.1% | 247,444 | +368.3% | 0.01% | – |
| Q4 2017 | $2,106,000 | -57.9% | 52,840 | -57.8% | 0.00% | -100.0% |
| Q3 2017 | $5,004,000 | +65.4% | 125,103 | +78.2% | 0.00% | +33.3% |
| Q2 2017 | $3,025,000 | +150.4% | 70,191 | +81.8% | 0.00% | +200.0% |
| Q1 2017 | $1,208,000 | -22.5% | 38,600 | -37.5% | 0.00% | 0.0% |
| Q4 2016 | $1,558,000 | +216.0% | 61,722 | +210.2% | 0.00% | – |
| Q3 2016 | $493,000 | -17.3% | 19,900 | -49.1% | 0.00% | -100.0% |
| Q1 2016 | $596,000 | -86.0% | 39,112 | -87.6% | 0.00% | -80.0% |
| Q4 2015 | $4,247,000 | +1813.1% | 316,011 | +1893.8% | 0.01% | – |
| Q3 2015 | $222,000 | -91.8% | 15,850 | -90.0% | 0.00% | -100.0% |
| Q2 2015 | $2,699,000 | +17.2% | 158,964 | -16.5% | 0.00% | 0.0% |
| Q1 2015 | $2,302,000 | +5.2% | 190,404 | -27.8% | 0.00% | 0.0% |
| Q4 2014 | $2,189,000 | +29.2% | 263,716 | +35.3% | 0.00% | 0.0% |
| Q3 2014 | $1,694,000 | +357.8% | 194,946 | +476.8% | 0.00% | – |
| Q2 2014 | $370,000 | -48.3% | 33,799 | -57.7% | 0.00% | -100.0% |
| Q1 2014 | $715,000 | +532.7% | 79,926 | +435.4% | 0.00% | – |
| Q4 2013 | $113,000 | +109.3% | 14,929 | +78.5% | 0.00% | – |
| Q2 2013 | $54,000 | – | 8,365 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |